[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Guadalajara\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":265},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,52,82,111,138,165,190,214,241],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100630434","evaluation-of-the-hepatoprotective-effects-of-a-nutritional-supplement-in-patients-with-liver-disease-secondary-to-chronic-hepatitis-c-virus-infection-resqueti-study-100630434",false,"NCT07487623","Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).","Evaluation of the Hepatoprotective Effects of a Nutritional Supplement Containing Resveratrol, Quercetin, Taurine, Inulin, and Whey Protein on Biochemical, Molecular, and Clinical Markers in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).","RESQUETI","Inclusion Criteria:\n\nPatients with liver disease secondary to chronic hepatitis C virus infection who attend the outpatient Hepatitis Clinic of the Gastroenterology Department at Hospital Civil Fray Antonio Alcalde.\n\nChild-Pugh score \\\u003C 8 points. Age 18-69 years. Both sexes. Signed informed consent.\n\n\\-\n\nExclusion Criteria:\n\n* Patients with alcohol consumption within the past 6 months. Patients with a history of acute-on-chronic liver failure (ACLF). Patients with persistent hepatic encephalopathy. Patients unable to perform frailty assessments. Patients with refractory ascites. Patients with a history of hepatorenal syndrome. Patients with a history of hepatopulmonary syndrome. Patients with chronic kidney disease. Patients with autoimmune diseases. Patients with any type of cancer. Patients with dementia or other significant mental illnesses. Use of protein supplements or probiotics.","ALL","18 Years","69 Years",{"count":21,"type":22},26,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this clinical trial is to evaluate whether a nutritional supplement containing resveratrol, quercetin, taurine, inulin, and whey protein improves biochemical and molecular markers, as well as clinical outcomes, in patients with liver disease related to chronic hepatitis C infection.\n\nThe study will compare the investigational supplement with an active control (whey protein alone) to determine whether the combination formulation provides additional benefits on liver-related biomarkers and clinical assessment.\n\nParticipants will:\n\nTake the investigational supplement or active control daily for 12 weeks.\n\nAttend clinic visits every 4 weeks for laboratory testing and clinical evaluations.",[28,29],"Liver Disease Chronic","HEPATITIS C VIRUS CHRONIC INFECTION",[31,32,33,34,35,36,37,38],"liver disease chronic","hcv","resveratrol","quercetin","taurine","inulin","frailty","whey protein","RECRUITING","2026-03-17",{"date":42,"type":43},"2026-03-23","ACTUAL",{"date":45,"type":43},"2025-10-11",{"date":47,"type":22},"2026-05-15",{"name":49,"class":50},"University of Guadalajara","OTHER",2,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100622898","effects-of-restricted-time-and-psychochrononutritional-feeding-in-people-with-metabolic-syndrome-100622898","NCT07389603","Effects of Restricted-time and Psychochrononutritional Feeding in People With Metabolic Syndrome","Effect of a Restricted Time and Psychochrononutritional Feeding Intervention Program on the Nutritional Status of People With Metabolic Syndrome in Ciudad Guzmán","PSICRONUT","Inclusion Criteria:\n\n* Age 18 to 60 years\n* Both sexes\n* Feeding window ≥14 h\u002Fday\n* Usual sleep duration \\>6.5 h\n* Individuals diagnosed with metabolic syndrome who meet three or more of the criteria from Panel III of the National Cholesterol Education Program's Adult Treatment Guidelines:\n\n  * Waist circumference: ≥102 cm for men, ≥88 cm for women\n  * Triglycerides: ≥150 mg\u002FdL or on treatment for hypertriglyceridemia\n  * High-Density Lipoprotein (HDL) cholesterol: \\\u003C40 mg\u002FdL for men, \\\u003C50 mg\u002FdL for women\n  * Blood pressure: systolic ≥130 mmHg and diastolic ≥85 mmHg or on treatment for hypertension\n  * Fasting plasma glucose: ≥100 mg\u002FdL\n* Individuals who provide informed consent\n\nExclusion Criteria:\n\n* (based on participant self-report unless medical records are available)\n\n  * Pregnancy or lactation\n  * Currently enrolled in a weight loss program\n  * Current treatment with antidepressants, medications that affect glucose metabolism or appetite, or immunosuppressant therapy\n  * History or presence of eating disorders\n  * Sleep apnea\n\nElimination Criteria:\n\n* Participants who do not attend more than two sessions of the psychochrononutritional intervention program.\n* Participants who decide to withdraw their consent to continue in the study at any time for any reason.","60 Years",{"count":62,"type":22},64,[25],"Metabolic syndrome is a cluster of risk factors, including abdominal obesity, high blood pressure, high triglycerides, and insulin resistance, that increase the risk of developing type 2 diabetes and cardiovascular disease. The prevalence of this syndrome is rising in Mexico. Recent research suggests that when we eat is as important as what we eat. Therefore, chrononutritional strategies such as time-restricted eating (TRE), where food intake is confined to a specific daily time window, have been developed and shown promising benefits. However, there are documented barriers to maintaining this nutritional strategy over time. Therefore, this study proposes that combining TRE with a psychochrononutritional program (integrating psychological, chronobiological, and nutritional components) will improve adherence to the nutritional strategy and lead to better health outcomes than only prescribing a specific eating window.\n\nTo this end, 64 adults (18-60 years old) with metabolic syndrome will be recruited in Ciudad Guzmán, Jalisco, Mexico. The TRE intervention will last eight weeks and include two groups. One group will undergo a psychochrononutritional intervention, whereas the other will receive only instructions regarding the eating window. Within each group, two subgroups will be formed: one assigned to an 8-hour eating window, and the other to a 10-hour window. Before and after the intervention, anthropometric, biochemical (lipid profile and plasma glucose), clinical (blood pressure), and dietary assessments will be performed. We expect reductions in blood pressure, glucose, triglycerides, and waist circumference as well as better adherence in the psychochrononutritional intervention group.",[66],"Metabolic Syndrome",[68,69,70,71,72],"Time restricted eating","Eating Behavior","Chrononutrition","Metabolic syndrome","Psychochrononutrition","2026-02-15",{"date":75,"type":43},"2026-02-18",{"date":77,"type":43},"2025-12-04",{"date":79,"type":22},"2026-06",{"name":49,"class":50},1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":90,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":51},"100586463","phase-2-effect-of-vitamin-e--tocopherol-on-clinical-activity-and-inflammation-in-rheumatoid-arthritis-100586463","NCT06915701","\"Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis\"","\"Evaluation of the Effect of Vitamin E (α-tocopherol) Supplementation on Clinical Activity and Inflammation in Patients With Rheumatoid Arthritis\"","VitE in RA","Inclusion criteria:\n\n* Female sex\n* RA classification (ACR\u002FEULAR 2010)\n* Early RA 2 years\n* Treatment with conventional synthetic FARMEs (Metrotexato, Hydroxychloroquine, Leflunomide, Sulfasalazina and their combinations)\n* DAS28 ≥3.2\n* Vitamin E intake deficiency (\\\u003C15mg\u002Fday)\n* No comorbidities\n* Age \\> 18 years\n* Voluntary participation and informed consent.\n\nExclusion Criteria:\n\n* Liver and kidney disease\n* Overlap syndrome\n* Coagulation disorders\n* Pregnancy\n* Consumption of supplements (iron, vitamin E, and K), and medications such as acetylsalicylic acid, amlodipine, estrogen, glucocorticoids and drugs used to treat dyslipidemias in the last three months.\n\nElimination Criteria:\n\n* Errors in administration of the 20% supplement\n* Adverse effects of the supplement\n* Pregnancy during the study\n* Insufficient blood sample\n* Voluntary withdrawal of informed consent.","FEMALE",{"count":92,"type":22},46,[94,95],"PHASE2","PHASE3","The objective of this clinical trial is to determine whether α-tocopherol (vitamin E) supplementation decreases inflammation and clinical activity in patients with rheumatoid arthritis (RA).The main questions to be answered are:\n\n* Is supplementation with vitamin E (α-tocopherol) for one month associated with decreased clinical activity and inflammation in patients with RA?\n\nResearchers will compare α-tocopherol with a placebo (a look-alike substance containing no active ingredient) to see if α-tocopherol effectively reduces inflammation and clinical activity in patients with rheumatoid arthritis.\n\nParticipants will:\n\n* Take two capsules (one in the morning and one in the afternoon) of either α-tocopherol or placebo every day for a month.\n* Attend clinic visits at the start of the intervention (baseline) and at the end of the month for final check-ups and tests.\n* Keep a diary to record your symptoms and how often you take α-tocopherol or placebo.",[98],"Rheumatoid Arthritis",[100,101,102],"Rheumatoid arthritis","Antioxidant","Vitamin E","2026-02-10",{"date":105,"type":43},"2026-02-13",{"date":107,"type":43},"2026-02-06",{"date":109,"type":22},"2027-01-15",{"name":49,"class":50},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":118,"maxAge":60,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":81},"100597301","effect-of-fenugreek-seed-administration-on-metabolic-syndrome-insulin-sensitivity-and-insulin-secretion-100597301","NCT07056712","Effect of Fenugreek Seed Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion","Effect of Fenugreek Seed Administration on the Components of Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion","Inclusion Criteria:\n\n* Men and women between 30 and 60 years old.\n* Diagnosis of Metabolic Syndrome (MS) according to the International Diabetes Federation (IDF) criteria.\n\nWaist circumference ≥90 cm in men and ≥80 cm in women, plus the presence of two or more of the following criteria:\n\n* Fasting glucose ≥100 mg\u002FdL or previous diagnosis of type 2 diabetes.\n* Systolic Blood Pressure ≥130 mmHg.\n* Diastolic Blood Pressure ≥85 mmHg.\n* Triglycerides ≥150 mg\u002FdL.\n* HDL cholesterol \\\u003C40 mg\u002FdL in men and \\\u003C50 mg\u002FdL in women.\n\n  * Body Mass Index between 25.0 and 34.9 kg\u002Fm².\n  * Stable weight during the 3 months prior to the start of the study (weight variation less than 10%).\n  * Not receiving pharmacological treatment for any component of MS, insulin sensitivity, and\u002For insulin secretion.\n  * Signed informed consent form.\n\nNon-Inclusion Criteria:\n\n* Suspected or confirmed pregnancy.\n* Breastfeeding period.\n* Fasting glucose ≥126 mg\u002FdL.\n* LDL cholesterol ≥155 mg\u002FdL.\n* Triglycerides ≥500 mg\u002FdL.\n* Systolic blood pressure ≥140 mmHg and diastolic blood pressure ≥90 mmHg.\n* Use of medications and\u002For supplements known to influence the study variables.\n* History of kidney, thyroid, liver disease, or ischemic heart disease.\n* Active smoker.\n* Not using an effective and stable contraceptive method.\n\nExclusion Criteria:\n\n* Voluntary withdrawal of informed consent.\n* Treatment adherence ≤80%.\n* Occurrence of a serious adverse event.\n* Loss to follow-up.","30 Years",{"count":120,"type":22},28,[25],"Fenugreek has been shown to have beneficial effects on various metabolic abnormalities associated with metabolic syndrome (MS). However, no clinical trials have evaluated its effect on all components of MS, insulin sensitivity, and insulin secretion. Therefore, the main objective of this study is to assess the effect of fenugreek seed administration versus placebo on the components of metabolic syndrome, insulin sensitivity, and insulin secretion.",[66],[66,125,126,127,128],"Fenugreek","Insulin Secretion","Insulin Sensitivity","Nutraceutic","NOT_YET_RECRUITING","2025-09-01",{"date":132,"type":43},"2025-09-08",{"date":134,"type":22},"2025-09-15",{"date":136,"type":22},"2026-09-15",{"name":49,"class":50},{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":146,"sex":17,"minAge":118,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":164,"locationsCount":81},"100581202","innuprec-nutrigenetic-intervention-for-the-prevention-of-cardiovascular-disease-100581202","NCT06847243","INNUPREC (Nutrigenetic Intervention for the Prevention of Cardiovascular Disease)","Effect of Nutrigenetic Intervention on Cardiovascular Biomarkers, Oxidative Stress and Antioxidant Capacity in Subjects with Abdominal Obesity","INNUPREC","Inclusion Criteria:\n\n* 30-65 years of age\n* Subjects who agree to participate in the study and all signed informed consent\n* Women with a waist circumference ≥ 88 cm and men ≥ 102 cm according to NCEP\u002FATPIII.\n\nExclusion Criteria:\n\n* Currently consuming any of the following drugs: NSAIDs, anticoagulants, hypoglycemic, or hypolipemic drugs\n* Diagnosed autoimmune diseases\n* Diagnosed cancer\n* Pregnancy and breastfeeding\n* Subjects who have undergone a dietary intervention at the time or up to 3 months prior\n* Subjects who wish to abandon the study",true,"65 Years",{"count":149,"type":22},60,[25],"Background: Abdominal obesity (AO) is a multifactorial disease that affects 81.6% of the Mexican population; it is characterized by the excessive accumulation of adipose tissue in abdominal region. Scientific evidence suggest that regional fat distribution plays a critical role in the development of cardiovascular diseases (CVD). The main processes involved in the increased risk of developing CVD in the presence of AO are alterations in insulin signaling, dyslipidemias, atherosclerosis, inflammation, and oxidative damage. On the last years has been reported genetic variations associated with AO and dyslipidemia. In addition, interactions have been found between these genetic variants and diet that may be influencing a differential response in metabolic, molecular, and phenotypic processes, which favor the development of CVD. Objective: Evaluate the effect of nutrigenetic intervention on cardiovascular biomarkers, oxidative stress and antioxidant capacity in subjects with abdominal obesity. Materials and methods: The present study is a simple randomized clinical trial. Participants will be randomized into one of two groups of intervention; Control group and Nutrigenetic group during a 2-month follow-up period. Anthropometric, dietary evaluation and biochemical markers assessments will be monitored at baseline, at 4 weeks (mid-intervention), and at 8 weeks (end of intervention). The dietary evaluation was analyzed by Nutritionist Pro software. Body composition was evaluated by electrical bioimpedance (InBody 370). All biochemical determinations were analyzed by dry chemistry (Vitros 350) and cardiometabolic markers by colorimetric immunoassay technology. Infrastructure: Institute of Translational Nutrigenomics and Nutrigenomics, University Center for Health Sciences, University of Guadalajara.",[153],"Abdominal Obesity",[155,156,157],"Abdominal obesity","Nutrigenetic intervention","Cardiometabolic biomarkers","2025-02-26",{"date":160,"type":43},"2025-03-03",{"date":162,"type":22},"2025-03-01",{"date":130,"type":22},{"name":49,"class":50},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":175,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":4},"100579814","phase-2-the-effect-of-curcumin-on-inflammatory-markers-in-hemodialysis-patients-100579814","NCT06829186","The Effect of Curcumin on Inflammatory Markers in Hemodialysis Patients","Effect of Curcumin on the Reduction of Cellular Inflammation Markers in Hemodialysis Patients","Inclusion Criteria:\n\n* Patients of both sexes undergoing dialysis or hemodialysis.\n* Aged 18 years or older.\n* Clinically stable and receiving hemodialysis or dialysis for at least three months before study enrollment.\n* Continuation of pharmacotherapy as prescribed by their physician.\n* Regular use of antioxidant supplements and turmeric consumption.\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Active malignant disease (diagnosed within the past five years).\n* Critical illness requiring respiratory or circulatory support.\n* Severe congestive heart failure (NYHA class IV).\n* Severe chronic systemic infectious or inflammatory disease.\n* Severe liver disease.\n* Known allergy to study products.\n* Treatment with immunosuppressants or experimental drugs in the past month.\n* Use of anti-inflammatory corticosteroids.\n* Scheduled kidney transplant during the study.\n* Pregnant patients.\n* Active smokers.\n* Autoimmune diseases, cancer, severe infections, or AIDS.","100 Years",{"count":174,"type":22},70,[94],"The goal of this clinical trial is to learn if curcumin can lower the inflammation in participants with chronic kidney disease (CKD) undergoing hemodialysis (HD).\n\nThe main questions it aims to answer are:\n\nDoes curcumin lower can lower profinflamatory markers in participants with CKD on HD?\n\nResearchers will compare curcumin to a placebo (a look-alike substance that contains no drug) to see if curcumin works to help the treatment in participants with CKD on HD.\n\nResearchers will compare nutritional status and side effects after taking the supplement.\n\nParticipants will:\n\nTake the curcumin or a placebo twice a day for 3 months Visit the clinic once every week for checkups and tests.",[178],"Hemodialysis",[180,178,181],"CURCUMIN","INFLAMMATION","2025-02-10",{"date":184,"type":43},"2025-02-17",{"date":186,"type":22},"2025-03-15",{"date":188,"type":22},"2026-12-30",{"name":49,"class":50},{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":118,"maxAge":60,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":198,"briefSummary":199,"conditions":200,"keywords":201,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":81},"100520850","phase-2-effect-of-celery-seed-on-the-components-of-metabolic-syndrome-insulin-sensitivity-and-insulin-secretion-100520850","NCT06061926","Effect of Celery Seed on the Components of Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion","Effect of Celery Seed (Apium Graveolens L.) Administration on the Components of Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion","Inclusion Criteria:\n\n* Patients both sexes\n* Age between 30 and 60 years\n* Diagnosis of metabolic syndrome (MS) according to the IDF criteria: waist circumference: ≥80 cm (women) ≥90 cm (men), plus two or more of the following:\n\n  * Fasting glucose ≥ 100 mg\u002FdL\n  * Triglycerides ≥150 mg\u002FdL\n  * HDL-c: Men ≤40 mg\u002FdL, women ≤50 mg\u002FdL\n  * Blood pressure ≥130\u002F85 mmHg\n* Body Mass Index from 25 to 34.9 kg\u002Fm²\n* Stable weight at least the previous last 3 months (weight variation less than 10%)\n* No pharmacological treatment for MS, insulin sensitivity and insulin secretion\n* Acceptance and signing of informed consent\n\nExclusion Criteria:\n\n* Pregnancy or breast-feeding\n* Glucose ≥126 mg\u002FdL\n* Total cholesterol ≥240 mg\u002FdL\n* Triglycerides ≥500mg\u002FdL\n* Systolic blood pressure ≥140 mmHg\n* Diastolic blood pressure ≥90 mmHg\n* Drugs or supplements consumption with proven properties that modify the behavior of the study variables.\n* History of kidney, liver or thyroid disease",{"count":120,"type":22},[94],"The Metabolic Syndrome (MS) is a cluster of cardiometabolic risk factors, which include abdominal obesity, hyperglycemia, dyslipidemia, and high blood pressure. MS is a global health problem, it represents a risk factor for the progression of cardiovascular disease, which constitute the main cause of mortality in the world and in Mexico. The current treatment involves lifestyle changes and pharmacological treatment for each of the components of MS, however, there is no single approved treatment to control all components. Celery seed (Apium graveolens L.) from the Apiaceae family contains the flavonoids apigenin and luteolin; essential oils such as d-limonene, selinene and phthalides such as 3-n-butylphthalide. Thanks to its bioactive components, celery seed has proven to be effective in treating individual MS disorders; however, most studies are in animal models and there are no clinical studies that evaluate its effectiveness on all components of the system. MS, insulin sensitivity and insulin secretion so it could appear as a new, safe and effective complementary therapy for the treatment of MS.\n\nThe aim of this study is to evaluate the effect of celery seed on the components of metabolic syndrome, insulin sensitivity, and insulin secretion.",[66],[202,66,203,204,205],"Celery seed","Insulin resistance","Insulin secretion","Insulin sensitivity","2024-10-21",{"date":208,"type":43},"2024-10-23",{"date":210,"type":43},"2023-05-20",{"date":212,"type":22},"2025-12",{"name":49,"class":50},{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":17,"minAge":221,"maxAge":222,"enrollmentInfo":223,"targetDuration":4,"studyType":23,"phases":225,"briefSummary":226,"conditions":227,"keywords":229,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":81},"100558835","effect-of-a-casein-and-gluten-free-diet-in-mexican-children-with-autism-spectrum-disorder-100558835","NCT06556290","Effect of a Casein and Gluten Free Diet in Mexican Children With Autism Spectrum Disorder","Effect of a Casein and Gluten Free Diet on Gastrointestinal Symptoms, Clinical Variables and Gut Microbiota Composition in Mexican Children With Autism Spectrum Disorder","Inclusion Criteria:\n\nChildren between 4-10 years old diagnosed with autism spectrum disorder using the criteria established in the ADOS scale and the CARS.\n\nExclusion Criteria:\n\nChildren who have received:\n\n* Antibiotics\n* Antimycotics\n* Probiotic supplements\n* Prebiotic supplements\n* Any medication that may alter the microbial composition of the patient, minimum one month prior to sampling.\n* Children on a strict dietary regimen other than a casein-free and gluten-free diet.\n* Children with celiac disease or who present any gluten-related disorder.\n* Children with allergy to dairy products.","4 Years","10 Years",{"count":224,"type":22},20,[25],"Assess the effect of a casein-free and gluten-free diet on gastrointestinal symptoms, clinical variables, and the composition of the intestinal microbiota in Mexican children with autism spectrum disorder.",[228],"Autism Spectrum Disorder",[230,231,232],"Gut microbiota","Gluten free diet","Casein free diet","2024-08-13",{"date":235,"type":43},"2024-08-16",{"date":237,"type":43},"2024-02-12",{"date":239,"type":22},"2025-07-31",{"name":49,"class":50},{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":17,"minAge":118,"maxAge":147,"enrollmentInfo":248,"targetDuration":4,"studyType":23,"phases":249,"briefSummary":250,"conditions":251,"keywords":254,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":259,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":81},"100457110","intake-of-nitrate-rich-vegetables-and-their-effect-on-inflammatory-molecules-and-oral-microbiota-of-patients-with-periodontitis-100457110","NCT05232331","Intake of Nitrate-rich Vegetables and Their Effect on Inflammatory Molecules and Oral Microbiota of Patients With Periodontitis","Effect of Nitrate-rich Vegetable Intake on Inflammatory Molecule Levels, Nitrate-reducing Capacity and Oral Microbiota Composition in Patients With Periodontitis","Inclusion Criteria:\n\n* Men and\u002For women from 30 to 65 years old\n* Voluntary participation and signing the written informed consent\n* Not receiving nutritional treatment at the time of uptake\n* Availability to attend all scheduled visits\n* Have an indication to receive nonsurgical periodontal treatment (NSPT)\n* Interdental clinical insertion loss ≥3mm and ≥5mm in the buccal or oral area of two or more non-adjacent teeth\n* Detectable depths ≥ 5mm in two or more teeth\n* Radiographic evidence of periodontal bone loss\n\nExclusion Criteria:\n\n* Trauma-Induced Gingival Recessions\n* Cervical caries\n* History of bleeding diathesis\n* Pregnant or nursing women\n* BMI \\\u003C18.5 kg \u002F m2\n* History of any of the following self-reported diseases: type 2 diabetes mellitus, high blood pressure, kidney or liver disease, inflammatory bowel diseases, autoimmune diseases and\u002F or use of medications to control these diseases.\n* Having or presenting a high risk of infection by tuberculosis, hepatitis B or Human Immunodeficiency Virus (HIV)\n* Use of antibiotics (including antibiotic oral rinse) 6 months prior to or during the study\n* Having received specialized periodontal treatment in the previous 6 months.\n* Smoking habit\n* Require an interpreter or not understand Spanish to attend or provide written material.",{"count":149,"type":22},[25],"Vegetables, mainly green leafy ones and some others like beets, are a rich source of nitrate. Nitrate metabolism has shown benefits to the body and there are recent studies that agree that the consumption of nitrates from vegetables can modify the oral microbiota by increasing species with nitrate-reducing capacity, which are also bacteria that are associated with oral health.",[252,253],"Periodontal Diseases","Periodontitis",[255,256,257,253,258],"Nitrates","Vegetables","Oral Microbiota","Inflammatory molecules",{"date":235,"type":43},{"date":261,"type":43},"2021-06-23",{"date":263,"type":22},"2025-12-31",{"name":49,"class":50},""]